Palantir Technologies Inc.Political scrutiny and criticism over NHS contract continuity create renewal risk and could affect future government contracts.

Palantir Technologies is facing renewed political scrutiny in the UK over its NHS federated data platform contract. Critics are questioning the National Health Service's reliance on a U.S. technology provider for critical data infrastructure, and a former NHS data leader has suggested that replacing Palantir before the next contract break point is unlikely, keeping attention on renewal risk. The debate could influence how governments view Palantir in other sensitive contracts, with investors focused on the security of the NHS relationship and what it signals about future international government work. Palantir's stock is at $129.3, up 11.8% over the past week, but down 4.6% over the past 30 days as the NHS scrutiny story develops.
Palantir Technologies Inc.Political scrutiny and criticism over NHS contract continuity create renewal risk and could affect future government contracts.